The Trump administration’s assault on government transparency represents a fundamental departure from decades of established practice and legal frameworks, with sweeping implications for public access to critical information. Most notably, the administration’s Department of Justice has concluded that the Presidential Records Act—a 50-year-old law requiring the preservation of presidential documents—should not exist, signaling intent to overturn or challenge this cornerstone of government accountability. This position comes alongside a broader pattern of removing previously public data from federal websites, restricting journalist access, and reversing transparency requirements across multiple agencies and industries.
The controversy encompasses everything from hidden executive branch spending to suppressed healthcare industry data, revealing a coordinated effort to reduce public oversight of federal operations. This article examines the specific transparency rollbacks the Trump administration has implemented or attempted, the legal battles already underway, and what these changes mean for citizens, businesses, and the press. We’ll break down the Presidential Records Act fight, the federal spending database controversy, data removal initiatives, healthcare and pharmacy transparency reversals, and the administration’s conflicting stance on disclosing classified material about unidentified anomalous phenomena.
Table of Contents
- Why Is Trump’s DOJ Rejecting the Presidential Records Act?
- How Courts Are Fighting Back on Federal Spending Transparency
- What Data Is Being Removed From Government Websites?
- Healthcare Industry Transparency—Rollback of AI Model Card Requirements
- Pharmacy Benefit Manager Transparency Rules Under Attack
- The UAP Disclosure Contradiction—Transparency for UFOs, Opacity Elsewhere
- What Comes Next—The Court Battles and Political Implications
- Conclusion
Why Is Trump’s DOJ Rejecting the Presidential Records Act?
The Presidential Records Act of 1978 was created in direct response to President Richard Nixon’s actions during Watergate, establishing that all documents created by a sitting president become federal property and must be preserved for the National Archives. By concluding the law should not exist, trump‘s Department of Justice is arguing for a fundamental rollback of post-Watergate governance standards. This position raises serious questions about congressional oversight, as any change to the act would require legislative action—either Congress passing new legislation to overturn it or legal challenges reaching the Supreme Court to strike it down as unconstitutional.
The broader context here matters: the Trump administration is simultaneously asserting that past presidents should have had the right to destroy or withhold records without accountability. This creates an unusual legal paradox where an administration argues both that a law shouldn’t exist going forward and that past violations of it shouldn’t carry consequences. The implications are extraordinary—if successful, future presidents could potentially handle documents with minimal oversight or preservation requirements.
How Courts Are Fighting Back on Federal Spending Transparency
Even as the administration rolled back transparency rules elsewhere, federal courts moved aggressively in the opposite direction on at least one critical issue: government spending disclosure. In March 2026, the White House Office of Management and Budget took down a federal website that disclosed how much money executive branch agencies were spending and on what. A federal district judge ordered the site restored, determining that the public has a right to know how taxpayer dollars are being allocated across the government.
When the Trump administration appealed this decision and requested an emergency stay to keep the spending database offline, the D.C. Circuit Court of Appeals unanimously rejected the request—meaning all three judges agreed that restoring transparency won. However, this victory remains fragile; the administration can continue fighting the case at lower court levels, and the outcome isn’t guaranteed long-term. The difference between a district court and appellate court is significant: a unanimous appeals court decision carries more weight, but the underlying legal question about whether the government must disclose this spending could still be litigated for years.
What Data Is Being Removed From Government Websites?
Beyond the spending database dispute, the Trump administration has systematically taken government webpages offline, deleting previously public vital data that citizens and researchers relied upon. The scale and scope of these removals are still being catalogued, but they include scientific data, health information, environmental records, and historical documents. Simultaneously, the administration has restricted journalists’ physical access to the White House and the Pentagon, limiting their ability to conduct reporting and ask questions of officials.
This represents a return to pre-internet-era government opacity, where information simply wasn’t available unless you filed a Freedom of Information Act (FOIA) request and waited months or years for a response. For example, environmental agencies removed air quality data, health agencies removed vaccination statistics, and education departments took down school safety records. The practical effect is that researchers, journalists, advocacy groups, and citizens no longer have immediate access to data that was previously available with a simple search. This deletion strategy is harder to challenge in court than the spending database issue because courts have been more reluctant to mandate that governments maintain or restore deleted websites.
Healthcare Industry Transparency—Rollback of AI Model Card Requirements
The Trump administration has proposed removing a requirement that companies using artificial intelligence in healthcare products must include “model cards” that document how the AI works, what data trained it, and what its limitations are. This transparency measure was designed to help doctors, regulators, and patients understand AI decision-making in medical settings—critical when algorithms influence diagnoses, treatment recommendations, or insurance coverage. California Attorney General Rob Bonta publicly opposed the rollback, arguing that removing these requirements would make it impossible to verify whether AI systems are performing fairly across different patient populations.
The tension here reveals a key limitation of the administration’s approach to transparency: it selectively applies deregulation while ignoring how opacity affects vulnerable populations. Healthcare AI affects treatment decisions that can be life-or-death matters. Removing certification requirements doesn’t mean the AI becomes safer or more effective—it simply means regulators and the public lose the ability to audit whether it’s working fairly. For patients, this represents a step backward; they may receive AI-assisted care without any public documentation of how that AI was trained or tested.
Pharmacy Benefit Manager Transparency Rules Under Attack
On February 2, 2026, Trump administration transparency rules affecting pharmacy benefit managers (PBMs) came into effect, requiring these middlemen in the prescription drug supply chain to disclose information about their pricing practices and formularies. PBMs control which drugs insurance plans cover and at what cost, making them central players in healthcare affordability—yet they’ve traditionally operated with minimal transparency. The new rules require disclosure of rebates, pricing methodologies, and other practices that directly affect what patients pay for medications.
However, there’s an important caveat: being “under Trump administration rules” doesn’t mean these rules will survive. The same administration that implemented them in February is now rolling back or weakening other transparency measures. Industry pressure from PBMs seeking to operate without disclosure requirements could lead to rule changes, either through direct repeal or through non-enforcement. For patients and consumer advocates, the pharmaceutical transparency landscape is increasingly uncertain; rules that seemed settled can be reversed through administrative action without congressional involvement.
The UAP Disclosure Contradiction—Transparency for UFOs, Opacity Elsewhere
In a striking contradiction to its broader transparency rollbacks, the Trump administration teased the disclosure of government files related to unidentified anomalous phenomena (UAP, the official term for UFOs). As of February 20, 2026, transparency advocates expressed cautious hope that the administration would release classified materials about UFO sightings, government investigations, and any evidence of non-terrestrial origin. This represents a rare instance of the administration positioning itself as pro-transparency—the exact opposite of its stance on spending databases, government data, and healthcare algorithms.
The UAP disclosure represents either genuine commitment to transparency on this specific issue or strategic positioning to appear pro-transparency while rolling back accountability elsewhere. The symbolism matters: the administration can point to UFO disclosure as evidence it supports transparency while simultaneously removing environmental data and suppressing healthcare information. For observers tracking transparency policy, this contradiction suggests the administration’s transparency philosophy is issue-specific rather than principled—transparency is good when it serves the administration’s interests, but bad when it enables oversight of spending, regulations, or business practices.
What Comes Next—The Court Battles and Political Implications
The federal courts have shown willingness to push back on at least some transparency rollbacks, as evidenced by the spending database decision. However, the Supreme Court’s current conservative majority hasn’t been broadly pro-transparency, and future litigation could go either way. The Presidential Records Act question is the highest-stakes issue; if courts rule that the act can’t be challenged, Congress would need to act, requiring Democratic support in a Republican-controlled Congress. That’s unlikely to happen, meaning the DOJ’s position could eventually become law through inaction and attrition.
Looking forward, the transparency landscape will depend on aggressive litigation by transparency advocates, journalists, and state attorneys general (like California’s Bonta) willing to challenge rollbacks. The federal judiciary is currently the primary check on these initiatives, making individual judge appointments and appellate court composition crucial. Meanwhile, Congress could pass legislation to strengthen or defend transparency requirements, but that would require political will that currently doesn’t exist. The next few years will determine whether the Trump administration’s transparency rollbacks are temporary policy choices or the beginning of a permanent shift toward less accountable government.
Conclusion
The Trump administration’s transparency controversies reveal a systematic effort to reduce public access to government information while simultaneously rolling back industry transparency requirements in healthcare and pharmacy. From the presidential records fight to the removal of federal data and the weakening of AI disclosure rules, the pattern is consistent: opacity is being restored to government at multiple levels.
However, courts have begun pushing back, most notably by restoring the federal spending database against the administration’s wishes, showing that transparency protections have legal defenders even when political will is lacking. Citizens, journalists, healthcare advocates, and business watchdogs should monitor ongoing litigation around the Presidential Records Act, support FOIA requests for data that was deleted from government websites, and pressure Congress to strengthen transparency laws rather than weaken them. The outcome of these battles will shape whether government remains publicly accountable or returns to pre-internet opacity standards that benefit those in power at the expense of public interest.